用于治疗多发性骨髓瘤的双特异性T细胞衔接器：成就与挑战
Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges.
作者信息
Alhallak Kinan, Sun Jennifer, Jeske Amanda, Park Chaelee, Yavner Jessica, Bash Hannah, Lubben Berit, Adebayo Ola, Khaskiah Ayah, Azab Abdel Kareem
机构信息
Department of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, MO 63108, USA.
Department of Biomedical Engineering, Washington University in St. Louis McKelvey School of Engineering, St. Louis, MO 63130, USA.
出版信息
Cancers (Basel). 2021 Jun 8;13(12):2853. doi: 10.3390/cancers13122853.
MM is the second most common hematological malignancy and represents approximately 20% of deaths from hematopoietic cancers. The advent of novel agents has changed the therapeutic landscape of MM treatment; however, MM remains incurable. T cell-based immunotherapy such as BTCEs is a promising modality for the treatment of MM. This review article discusses the advancements and future directions of BTCE treatments for MM.
多发性骨髓瘤（MM）是第二常见的血液系统恶性肿瘤，约占造血系统癌症死亡人数的20%。新型药物的出现改变了MM的治疗格局；然而，MM仍然无法治愈。基于T细胞的免疫疗法如双特异性T细胞衔接器（BTCEs）是治疗MM的一种有前景的方式。这篇综述文章讨论了BTCEs治疗MM的进展和未来方向。
Zotero 插件